Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma

Inclusion Criteria: * Differentiated non-keratinizing carcinoma and undifferentiated non-keratinizing carcinoma confirmed by pathology; * The staging is T1-2N0-1M0 (except T1N0M0) (UICC 8th edition); * Initial treatment patients who have not received anti-tumor therapy; * No history of other malignant tumors; * Male or female, aged 18 to 70 years old; * Liver and kidney function: total bilirubin ≤ upper limit of normal (ULN); AST and ALT ≤ 2.5 times ULN; alkaline phosphatase ≤ 5 times ULN; creatinine clearance ≥ 80 mL/min; * Neutrophil count (ANC) ≥2×109/L, platelet count ≥100×109/L and hemoglobin ≥9 g/dL; * No serious heart, lung, liver, kidney and other important organ dysfunction; * Karnofsky score ≥70 points; * Sign the informed consent form; * Able to follow research protocols and follow-up procedures. Exclusion Criteria: * Anti-tumor treatment has been performed, including chemotherapy, radiotherapy, and surgery; * Find distant metastases before treatment; * Women who are pregnant or breastfeeding; * Disagree to sign the informed consent form; * Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographic reasons; * Simultaneously accept experimental treatment of other clinical research (in the treatment period of clinical research); * Known to be allergic to possible chemotherapy drugs; * Patients with other malignant tumors; * Accompanied by severe uncontrollable infections or medical diseases, including autoimmune diseases; * Major organ dysfunction, such as decompensated heart, lung, kidney, and liver failure, cannot tolerate radiotherapy and chemotherapy; * Laboratory examination: total bilirubin\>upper limit of normal (ULN); AST and/or ALT\>1.5 times ULN and accompanied by alkaline phosphatase\>2.5 times ULN; * Any uncertain factors that affect patient safety or compliance.